Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Endocrinol Invest ; 47(1): 101-113, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37314685

RESUMEN

CONTEXT: Cushing syndrome (CS) is associated with different hematological abnormalities. Nevertheless, conflicting data about erythropoiesis in CS have been reported. Furthermore, it is unclear whether CS sex and subtype-specific alterations in red blood cells (RBC) parameters are present. OBJECTIVE: To investigate sex and subtype-specific changes in RBC in patients with CS at initial diagnosis and after remission. DESIGN: Retrospective, monocentric study including 210 patients with CS (women, n = 162) matched 1:1 for sex and age to patients with pituitary microadenomas or adrenal incidentalomas (both hormonally inactive). RBC parameters were evaluated at initial diagnosis and after remission. RESULTS: Women with CS had higher hematocrit (median 42.2 vs 39.7%), hemoglobin (14.1 vs 13.4 g/dl) and mean corpuscular volume (MCV) (91.2 vs 87.9 fl) compared to the controls (all p < 0.0001). Women with Cushing disease (CD) showed higher hematocrit, RBC and hemoglobin levels than those with ectopic Cushing (ECS) (all p < 0.005). Men with CS had lower hematocrit (42.9 vs 44.7%), RBC count (4.8 vs 5.1n*106/µl) and hemoglobin (14.2 vs 15.4 g/dl), but higher MCV (90.8 vs 87.5 fl) than controls (all p < 0.05). In men with CS, no subtype-specific differences were identified. Three months after remission hemoglobin decreased in both sexes. CONCLUSION: CS is characterized by sexual and subtype-specific differences in RBC parameters. Compared to controls, women with CS showed higher hematocrit/hemoglobin levels, whereas men had lower hematocrit/hemoglobin, which further decreased directly after remission. Therefore, anemia should be considered as complication of CS in men. In women, differences in RBC parameters may help to differentiate CD from ECS.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Síndrome de Cushing , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT) , Masculino , Humanos , Femenino , Eritropoyesis , Estudios Retrospectivos , Hematócrito , Hemoglobinas
2.
J Endocrinol Invest ; 47(1): 223-234, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37354248

RESUMEN

PURPOSE: Brain metastases rarely complicate the natural history of patients with adrenocortical carcinoma (ACC). No information is available regarding the life expectancy and efficacy of treatments in ACC patients with brain involvement. METHODS: A pooled analysis was performed by searching on PubMed and using the keywords: "brain metastases in adrenocortical carcinoma", and "leptomeningeal metastases in adrenocortical carcinoma". Four patients diagnosed at Spedali Civili Hospital in Brescia were added to the analysis. Data concerning demographic, disease characteristics, adopted treatments and patient prognosis were collected. RESULTS: A total of 27 patients (18 adults and 9 children) were included in this study, 22 of them had an adequate follow-up. Brain metastases occurred late in the natural history of adult patients but not in that of children. Surgery plus/minus radiation therapy was the treatment of choice. Adult patients with brain metastases had a poor prognosis with a median progression-free survival (PFS) and overall survival (OS) of 2 and 7 months, respectively. Median PFS and OS were not attained in children. CONCLUSION: Brain metastases in ACC patients are rare and are associated with poor prognosis, particularly in adults. Surgery plus/minus radiotherapy is the only therapeutic approach that can offer patients a chance to obtain durable local disease control.


Asunto(s)
Neoplasias de la Corteza Suprarrenal , Carcinoma Corticosuprarrenal , Neoplasias Encefálicas , Adulto , Niño , Humanos , Carcinoma Corticosuprarrenal/patología , Resultado del Tratamiento , Pronóstico , Neoplasias Encefálicas/terapia , Neoplasias de la Corteza Suprarrenal/patología , Estudios Retrospectivos
3.
J Athl Train ; 27(2): 102-10, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-16558144

RESUMEN

Piriformis syndrome is a questionable clinical entity that has been cited as a cause of buttock pain and sciatica. The intimate relationship between the piriformis and the sciatic nerve has been suspected as being the source of the signs and symptoms that often appear following minor trauma to the pelvic or buttock region. Muscle function is an important consideration in the evaluation and treatment of the athlete with suspected piriformis syndrome. The action of the piriformis muscle on the hip varies as the hip moves from a neutral to a flexed position. While in a flexed position, the piriformis internally rotates and abducts the hip; however, in a neutral position, the piriformis acts as an external rotator of the hip. A comprehensive evaluation provides the information necessary to design a treatment plan specific to the involved structures, while meeting the functional needs of the individual athlete. This paper describes the anatomy, pathomechanics, physical examination, and treatment options relevant to the piriformis syndrome. Treatment protocols stressing exercises that promote strength, flexibility, and functional activities are believed to be essential in restoring the athlete's ability to return to pain-free competition.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA